中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

155 records (took 0.015 seconds)

    Cancer-associated SCM-recognition factor, preparation and method of use
    41.
    发明授权
    Cancer-associated SCM-recognition factor, preparation and method of use 失效
    癌症相关SCM识别因子，制备方法和使用方法

    公开(公告)号：US5270171A

    公开(公告)日：1993-12-14

    申请号：US539686

    申请日：1990-06-18

    Applicant: Boris Cercek ,  Lea Cercek

    Inventor： Boris Cercek ,  Lea Cercek

    IPC: A61K38/00 ,  A61K35/16 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P35/00 ,  C07K1/20 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/47 ,  C07K14/585 ,  C07K14/81 ,  C07K16/00 ,  C07K16/18 ,  C12N1/21 ,  C12N15/12 ,  C12P21/08 ,  G01N33/50 ,  G01N33/53 ,  G01N33/574 ,  C12Q1/02 ,  A61K37/02 ,  A61K35/14 ,  A61K37/04 ,  C07K5/00 ,  C07K7/00 ,  C07K15/00 ,  C07K17/00 ,  C07K ,  C07K13/00

    CPC classification number: A61K35/16 ,  A61K47/48546 ,  C07K14/4745 ,  C07K14/585 ,  C07K16/18 ,  C07K7/08 ,  G01N33/5011 ,  G01N33/5091 ,  A61K38/00 ,  Y10S436/811 ,  Y10S436/813

    Abstract: A cancer recognition factor (SCM factor) useful in the performance of the structuredness of the cytoplasmic matrix (SCM) test has been isolated, purified to substantial homogeneity, and characterized, and methods for its use have been described. The factor is a peptide of at least 9 amino acid residues including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to that of the sequence F-L-M-I-D-Q-N-T-K and produces at least a 10 percent decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer. A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening of blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple action spectrum of the SCM factor including cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor by cancer cells, represents a novel target for cancer management. Methods for reducing in vivo activity of the SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.

    Abstract translation: 已经分离了用于实现细胞质基质（SCM）测试结构化的癌症识别因子（SCM因子），将其纯化至基本均匀，并进行了表征，并描述了其使用方法。 该因子是至少9个氨基酸残基的肽，包括9个氨基酸残基的核心序列，其具有与序列FLMIDQNTK基本上相同的两亲性分布，并且产生SCM-1的细胞内荧光偏振值的至少10％的降低， 来自患有癌症的捐助者的淋巴细胞反应。 表示M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K的共有序列的合成SCM因子是完全活性的。 针对SCM因子的抗体可用于可以检测该因子的免疫测定，包括在体外生长的癌细胞中的检测。 SCM因子可用于筛选血液样本和其他体液或细胞抽吸物，以供应者中存在恶性肿瘤。 包括癌症增殖和侵袭促进在内的SCM因子的多重作用谱，以及宿主的免疫防御机制的抑制以及癌细胞对SCM因子的合成代表了癌症管理的新靶点。 用于降低SCM因子的体内活性的方法，例如透析或抗体中和，也可用于治疗癌症。

    Monoclonal antibodies for measuring okadaic acid
    42.
    发明授权
    Monoclonal antibodies for measuring okadaic acid 失效
    用于测量冈田酸的单克隆抗体

    公开(公告)号：US5264556A

    公开(公告)日：1993-11-23

    申请号：US858991

    申请日：1992-03-27

    Applicant: Hanna Sikorska ,  William S. Shestowsky

    Inventor： Hanna Sikorska ,  William S. Shestowsky

    IPC: C07K16/42 ,  C12P21/08 ,  C07K15/00

    CPC classification number: C07K16/4208

    Abstract: The present invention relates to an anti-idiotypic monoclonal antibody raised against a mouse monoclonal antibody or fragments thereof specific to at least one diarrhetic shellfish poisoning toxin selected from the group consisting of okadaic acid and derivatives thereof. The anti-idiotypic antibody is characterized by reacting only with antibodies to okadaic acid and derivatives thereof but not with antibodies directed against any other compounds. The anti-idiotypic antibody is further characterized by being an internal image of okadaic acid and derivatives thereof. A hybridoma producing an anti-idiotypic antibody in accordance with the present invention has been deposited at the ATCC under accession number HB 10768. Competitive solid-phase assays for determining the amount of okadaic acid and derivatives thereof in marine samples are also provided in accordance with the present invention. The present invention also relates to a kit for determining the amount of okadaic acid and derivatives thereof in marine samples.

    Biotinylating agents
    47.
    发明授权
    Biotinylating agents 失效
    生物素化剂

    公开(公告)号：US4794082A

    公开(公告)日：1988-12-27

    申请号：US92739

    申请日：1987-09-03

    Applicant: Gerald F. Sigler

    Inventor： Gerald F. Sigler

    IPC: C07D495/04 ,  C07K15/00 ,  C07K17/02 ,  C07K17/06

    CPC classification number: C07D495/04 ,  Y10S435/849

    Abstract: Compounds having a dithiopyridyl moiety linked to a biotin moiety are useful as thiol specific biotinylating agents. The biotin label can be cleaved in a reducing environment to yield the native thiol.

    Abstract translation: 具有与生物素部分连接的二硫代吡啶基部分的化合物可用作硫醇特异性生物素化剂。 生物素标记可以在还原环境中裂解，得到天然硫醇。

    Human soluble immune response suppressor
    48.
    发明授权
    Human soluble immune response suppressor 失效
    人类可溶性免疫反应抑制剂

    公开(公告)号：US4771125A

    公开(公告)日：1988-09-13

    申请号：US850207

    申请日：1986-04-10

    Applicant: H. William Schnaper ,  Thomas M. Aune

    Inventor： H. William Schnaper ,  Thomas M. Aune

    IPC: G01N33/50 ,  G01N33/68 ,  C07K15/00

    CPC classification number: G01N33/50 ,  G01N33/6863

    Abstract: Human soluble immune response suppressor (SIRS) having a molecular weight of about 10,000 to 15,000, an isoelectric point of about 7 and a defined amino acid composition distinctly different from murine SIRS is produced from a culture of MOLT-4 cells.

    Abstract translation: 从MOLT-4细胞的培养物产生具有约10,000至15,000的分子量，约7的等电点和明显不同于小鼠SIRS的确定的氨基酸组成的人可溶性免疫应答抑制（SIRS）。

    Method and agents for measuring protein aging
    49.
    发明授权
    Method and agents for measuring protein aging 失效
    测定蛋白质老化的方法和试剂

    公开(公告)号：US4761368A

    公开(公告)日：1988-08-02

    申请号：US885967

    申请日：1986-07-15

    Applicant: Anthony Cerami

    Inventor： Anthony Cerami

    IPC: G01N33/02 ,  G01N33/533 ,  G01N33/58 ,  G01N33/68 ,  C07K15/00 ,  G01N33/48

    CPC classification number: G01N33/6842 ,  G01N33/02 ,  G01N33/533 ,  G01N33/582 ,  G01N33/68 ,  Y10S435/81 ,  Y10S436/815 ,  Y10S530/807

    Abstract: A new and useful fluorescent chromophore has been isolated and identified which has been observed in proteins exposed to glucose over time, and whose fluorescent properties closely resemble those of the polypeptide after it undergoes advanced glycosylation. The chromophore has been structurally identified and named 2-furoyl-4(5)-(2-furanyl)-1H-imidazole, and is believed to be one of the end products of extended nonenzymatic polypeptide glycosylation, which results in the state known as nonenzymatic browning (NEB). The measurement of this chromophore makes possible both qualitative and quantitative assessment of the degree of aging. Diagnostic and test kits are also disclosed.

    Abstract translation: 已经分离和鉴定了一种新的和有用的荧光发色团，其已经在随时间暴露于葡萄糖的蛋白质中观察到，并且其荧光特性在经历高级糖基化之后与多肽的那些非常相似。 发色团已被结构鉴定并命名为2-糠酰基-4（5） - （2-呋喃基）-1H-咪唑，并且被认为是扩展的非酶多糖糖基化的最终产物之一，其导致称为 非酶褐变（NEB）。 这种发色团的测量使得可以对老化程度进行定性和定量评估。 还公开了诊断和测试试剂盒。

Patent Agency Ranking